These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22277680)

  • 21. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
    Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
    Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
    J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L
    Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C
    Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial.
    Chung CY; Lin SF; Chen PM; Chang MC; Kao WY; Chao TY; Hsiao LT; Yen CC; Yang MH; Hwang WS; Lin TL; Chiou TJ; Chang CS
    Anticancer Res; 2012 Aug; 32(8):3415-9. PubMed ID: 22843924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Sekeres MA
    Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
    Huang X; Liu Y; Liu R; Zou X; Yang H
    Hematology; 2023 Dec; 28(1):2274149. PubMed ID: 37908176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
    List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
    Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
    Bejanyan N; Tiu RV; Raza A; Jankowska A; Kalaycio M; Advani A; Chan J; Saunthararajah Y; Mooney L; Maciejewski JP; Sekeres MA
    Cancer; 2012 Aug; 118(16):3968-76. PubMed ID: 22180010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes.
    Candoni A; Raza A; Silvestri F; Lisak L; Galili N; Mumtaz M; Kikic F; Fanin R
    Ann Hematol; 2005 Jul; 84(7):479-81. PubMed ID: 15800786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.